Raymond James downgraded Third Harmonic Bio (THRD) to Market Perform from Outperform.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THRD:
- Morning Movers: Lattice Semiconductor, SelectQuote jump after earnings reports
- Third Harmonic Bio, Inc. Announces Restructuring Plan
- Third Harmonic Bio announces Phase 1 clinical results for THB335
- Third Harmonic halting non-THB335 research, reducing workforce by 50%
- Third Harmonic Bio price target lowered to $7 from $15 at Jefferies